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Abstract
Objectives. Chemokines are essential contributors to leucocyte accumulation at sites of inflammatory
pathology. Interfering with chemokine or chemokine receptor function therefore represents a plausible
therapeutic option. However, our currently limited understanding of chemokine orchestration of inflamma-
tory responses means that such therapies have not yet been fully developed. We have a particular interest
in the family of atypical chemokine receptors that fine-tune, or resolve, chemokine-driven responses. In
particular we are interested in atypical chemokine receptor 2 (ACKR2), which is a scavenging receptor for
inflammatory CC-chemokines and that therefore helps to resolve in vivo inflammatory responses. The
objective of the current study was to examine ACKR2 expression in common arthropathies.
Methods. ACKR2 expression was measured by a combination of qPCR and immuno-histochemistry. In
addition, circulating cytokine and chemokine levels in patient plasma were assessed using multiplexing
approaches.
Results. Expression of ACKR2 was elevated on peripheral blood cells as well as on leucocytes and
stromal cells in synovial tissue. Expression on peripheral blood leucocytes correlated with, and could
be regulated by, circulating cytokines with particularly strong associations being seen with IL-6 and hep-
atocyte growth factor. In addition, expression within the synovium was coincident with aggregates of
lymphocytes, potentially atopic follicles and sites of high inflammatory chemokine expression. Similarly
increased levels of ACKR2 have been reported in psoriasis and SSc.
Conclusion. Our data clearly show increased ACKR2 in a variety of arthropathies and taking into account
our, and others’, previous data we now propose that elevated ACKR2 expression is a common feature of
inflammatory pathologies.
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Rheumatology key messages
. ACKR2 expression is elevated within peripheral blood mononuclear cells from patients with a PsA and RA.
. CKR2 expression correlates with, and can be induced by, inflammatory cytokines and CC-chemokines in RA.
. Elevated ACKR2 expression is a consistent feature of inflammatory disease.
Introduction
The in vivo migration of leukocytes is regulated by pro-
teins belonging to the chemokine family [1]. This family is
defined on the basis of the presence of a conserved cyst-
eine motif in the mature protein sequence and is further
divided into CC, CXC, XC and CX3C subfamilies accord-
ing to the specific nature of the cysteine motif.
Chemokines can be broadly classified as being either in-
flammatory or homeostatic depending on the contexts in
which they function [2, 3]. Inflammatory chemokines are
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predominantly involved in recruiting inflammatory leuco-
cytes to damaged or infected tissue sites, whereas
homeostatic chemokines are involved in more precise
tissue localization of leucocytes. Chemokines interact
with their target cells through receptors belonging to the
seven transmembrane spanning family of G-protein-
coupled receptors [4]. There are 19 identified chemokine
receptors and, again, these are broadly distributed into
inflammatory and homeostatic subclasses. Given the es-
sential roles played by chemokines and their receptors in
regulating immune and inflammatory leucocyte migration,
it is not surprising that they play essential roles in a broad
range of autoimmune and inflammatory pathologies [5, 6].
Disappointingly, despite two decades of study, there are
currently no antagonists of chemokine receptor function
licensed for use in inflammatory diseases. This represents
a significant failing in the field and is likely to be related to
our currently poorly developed understanding of the full
complexities of the chemokine orchestration of inflamma-
tory responses [6].
In addition to the classical signalling chemokine recep-
tors there exists a separate subclass of receptors char-
acterized by an inability to mount typical signalling
responses to chemokine binding [7]. These receptors
also possess an altered DRYLAIV motif in the second
intracellular loop and have been named atypical chemo-
kine receptors on this basis. There are currently four
members of the atypical chemokine receptor family
[79]: ACKR1 (formerly known as DARC), ACKR2 (formerly
known as D6 or ccbp2), ACKR3 (formerly known as RDC1
or CXCR7) and ACKR4 (formerly known as CCRL1 or
CCXCKR). These molecules serve essential in vivo func-
tions in fine-tuning, or resolving, chemokine-driven re-
sponses and represent important new contributors to
the overall regulation of chemokine function.
We have a particular interest in ACKR2, which is a
highly promiscuous receptor for inflammatory CC-chemo-
kines and which is expressed by lymphatic endothelial
cells, syncytiotrophoblasts and some subsets of leuco-
cytes [10, 11]. Following ligand binding, ACKR2 internal-
izes ligands and targets them for intracellular degradation
[12, 13]. It is therefore a scavenging receptor for inflam-
matory CC-chemokines and its broad promiscuity
ensures that it can scavenge essentially all CC-chemo-
kines involved in inflammatory responses. Work from us,
and others, has demonstrated a clear role for ACKR2 in
the resolution of inflammatory responses at all tissue sites
at which it is expressed [1420]. In addition we recently
demonstrated a role for ACKR2 in lymphatic vessel devel-
opment [21]. We have also previously shown marked
up-regulation of ACKR2 expression in the epidermis and
peripheral blood in psoriasis [22], and whole skin and per-
ipheral blood in systemic sclerosis [23]. Others have fur-
ther shown ACKR2 overexpression in chronic obstructive
pulmonary disease [24] and post-myocardial infarction tis-
sues [25] suggesting an, as yet poorly defined, association
with inflammatory disease. The purpose of the current
study was to extend these analyses to incorporate inflam-
matory arthropathies, where ACKR2-binding inflammatory
CC-chemokines such as CC chemokine ligand (CCL) 1, 2,
3 and 5 play key roles in the propagation and maintenance
of synovitis [2632].
Methods
Ethics statement
This study was approved by the West of Scotland
Research Ethics Committee and the University of
Glasgow Medical, Veterinary and Life Sciences Ethics
Committee. Written consent was obtained from all partici-
pants according to the Declaration of Helsinki.
Isolation of peripheral blood mononuclear cells and
plasma
Heparinized whole blood (10 ml) was taken from healthy
donors and inflammatory arthritis patients (early RA, es-
tablished RA and PsA). Matched serum samples (10 ml)
were taken from each patient. Heparinized blood was
diluted 1:1 with wash buffer [PBS supplemented with
1% fetal calf serum (FCS) and 2 mM ethylenediaminete-
traacetic acid (EDTA)] and layered onto Histopaque (cat
no. 1077-1, Sigma-Aldrich, St Louis, MO, USA) according
to the manufacturer’s instructions. Blood was centrifuged
at 400 g for 30 min (with the brake removed) and the buffy
layer was extracted. Cells were washed twice with wash
buffer and counted using a haemocytometer. Cells were
either resuspended in RLT buffer (cat. no. 74004, Qiagen,
Hilden, Germany), containing b-mercaptoethanol, and
stored at 80C for future RNA isolation or resuspended
at 1  106/ml in complete media (RPMI + 10% FCS + 2 mM
L-glutamine + penicillin/streptomycin) for future cell cul-
ture. Plasma samples were centrifuged at 500g for
10 min at 4C and serum was stored in 500 ml aliquots at
80C for later analysis.
Quantitative real time RT-PCR
Peripheral blood mononuclear cell (PBMC) samples stored
in RLT buffer at 80C were thawed at room temperature
and RNA was extracted using the RNeasy micro kit (Qiagen
cat. no. 74004) according to the manufacturer’s instruc-
tions. RNA concentrations and quality were measured
using the Nanodrop-2000 (Thermo Fisher Scientific,
Waltham, MA, USA) and stored at 80C for future cDNA
synthesis. RNA was thawed and was reverse-transcribed
to cDNA (500 ng) using Affinity Script (cat. no. 600559,
Agilent Technologies, Santa Clara, CA, USA) according to
the manufacturer’s instructions. cDNA was stored at
20 C until used for quantitative real-time RT-PCR
(qPCR) using methodology and primers as described pre-
viously [3335]. Samples were run for 40 cycles on the
7900HT Fast Real-Time PCR System (ABI) and data were
analysed using ABI Prism SDS software (Thermo Fisher
Scientific). The absolute number of ACKR2 copies was nor-
malized to TATA-binding protein copy number.
Quantification of cytokines and chemokines
Plasma cytokines and chemokines were quantified
using the human cytokine 30-plex luminex kit (cat.
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no. LHC6003, Thermo Fisher Scientific). The serum was
analysed undiluted. The detection level of the luminex was
30 pg/ml; all readings lower than this were designated
non-detectable.
Immunofluorescence staining of synovial tissue
Paraffin-embedded RA synovial tissue was sliced into
5mm sections and mounted onto Superfrost slides (cat.
no. 631-0108 VWR, Hunter Boulevard, Magna Park,
Lutterworth, Leicestershire, UK). Sections were rehy-
drated to water through xylene and successive concen-
trations of alcohol. Antigen was retrieved by boiling slides
in 0.05 M citrate buffer (pH 6) for 8 min before slides were
blocked for 30 min at room temperature (RT) in 20% horse
serum (cat. no. S-2000, Vector Laboratories, Burlingame,
CA, USA) and biotin block (Vector Laboratories cat. no.
SP-2001) diluted in Tris-buffered saline containing 0.01%
Tween-20 (TBST). Slides were then incubated overnight at
4C with rabbit anti-human CCBP2 (ACKR2, 2.5 mg/ml,
Sigma-Aldrich cat. no. HPA013819) at 4C in Dako
REAL antibody diluent (cat. no. S2022, Dako,
Carpenteria, CA, USA) supplemented with 2.5% horse
serum2.5% human serum (Sigma-Aldrich cat. no.
H4522) and biotin block (Vector Laboratories cat. no.
SP-2001). The following morning, slides were washed in
TBST and incubated for a further 30 min at RT with bioti-
nylated horse anti-rabbit IgG (1/200, Vector Laboratories
cat. no. BA-1100) in Dako REAL antibody diluent supple-
mented with 2.5% horse serum2.5% human serum.
Slides were washed in TBST and incubated with
Fluorescein Avidin-D (1/500, Vector Laboratories cat. no.
A2001) for 40 min at RT.
Slides were then washed twice in TBST, and re-blocked
with 20% horse serum (Vector Laboratories cat. no. S-
2000) and Avidin-D block (Vector Laboratories cat. no.
SP-2001) diluted in TBST for 30 min at RT. Slides were
washed and stained with antibodies against lineage mar-
kers overnight at 4C in order to detect ACKR2+ macro-
phages: mouse IgG1 anti-human CD68 (clone PG-M1, 1
mg/ml; Dako cat. no. M0876); mast cells: mouse IgG anti-
human mast cell tryptase (clone AA1, 0.43 mg/ml; Dako cat.
no. M7052); CD3+ T cells: mouse IgG1 anti-human CD3
(clone LN10, 1mg/ml, Vector labs cat. no. VP-C429);
CD20+ B cells: mouse IgG2a anti-human CD20cy (clone
L26, Dako cat. no. M0755) or mouse IgG1 anti-human
CCL3 (clone 93321, cat. no. MAB270, R&D Systems,
Minneapolis, MN, USA). The following day, sections were
incubated with biotinylated horse anti-mouse IgG H + L
(Vector Laboratories cat. no. BA-2000) and subsequently
stained with Avidin-D Texas Red (Vector Laboratories cat.
no. A2006) for 40 min. Slides were washed, mounted using
Vectashield mounting medium with 40,6-diamidino-2-phe-
nylindole (DAPI; Vector Laboratories cat. no. H1200) and
analysed on an epifluorescence imaging microscope (Carl
Zeiss, Oberkochen, Germany). Images were captured using
Zeiss AxioVision software v. 4.8.2.
Immunofluorescence staining of cell cytospins
PBMCs were isolated as described above and resus-
pended in PBS containing 2 mM EDTA at 0.5  106/ml.
Cells (0.1  106) were spun onto superfrost slides (VWR)
at 800 r.p.m. for 3 min using a Shadon Cytospin
Centrifuge (Thermo Fisher Scientific), fixed in 100%
methanol for 10 min at RT and left to air dry. Slides were
then blocked with 20% horse serum (Vector Laboratories
cat. no. S-2000) diluted in TBST, before being stained
overnight at 4C with rabbit anti-human CCBP2 (ACKR2,
2.5 mg/ml, Sigma-Aldrich cat. no. HPA013819), mouse
IgG1 anti-human CD3 (Dako) and mouse IgG2a anti-
human CD20 (Dako). Antibodies were diluted in TBST
supplemented with 2.5% horse serum (Vector
Laboratories cat. no. S-2000) and 2.5% human serum
(Sigma-Aldrich cat. no. H4522). The following day, slides
were washed and incubated with goat anti-rabbit fluores-
cein isothiocyanate (1/300, cat. no. 4030-02), goat
anti-mouse IgG1 Cy5 (1/300 cat. no. 1070-15) and goat
anti-mouse IgG2a tetramethylrhodamine (1/300, cat. no.
1080-03, all from Southern Biotech, Birmingham, AL,
USA) in TBST containing 2.5% horse serum2.5%
human serum for 30 min at RT. Slides were washed,
mounted using Vectashield mounting medium with DAPI
(Vector Laboratories cat. no. H1200) and analysed on an
epifluorescence imaging microscope (Carl Zeiss). Images
were captured using AxioVision software v. 4.8.2.
Stimulation of PBMCs to detect ACKR2 expression
PBMCs were cultured at 1  106/ml in six-well plates in
complete media (RPMI + 10% FCS+ 2 mM L-glutam-
ine + penicillin/streptomycin) at 37C for 6, 24 or 48 h
with combinations of cytokines or chemokines, all from
Peprotech (Rocky Hill, NJ, USA) at 100 ng/ml. Cells were
harvested on ice, and processed for qPCR as described
above.
Statistical analysis
For all statistical tests, non-parametric data were ana-
lysed using the MannWhitney U test and parametric
data using Student’s unpaired t test. To detect significant
correlation between variables, Spearman’s correlation co-
efficient was used, where r = 1 denotes a perfect positive
correlation and r = 1 a perfect negative correlation.
P< 0.05 denotes significant differences.
Results
Patient cohort
A summary of the patient details is shown in supplemen-
tary Table S1, available at Rheumatology Online. Patients
classified as early RA (early inflammatory disease) were
defined as having a disease course of< 1 year and had
been taking DMARDs for <6 months. All patients with RA
and PsA had been treated with DMARDs for the majority
of the duration of their disease (over 1 year). There were no
significant differences in ESR or CRP between the patient
groups (supplementary Fig. S1A and B, available at
Rheumatology Online).
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ACKR2 expression is elevated in PBMCs from
inflammatory arthritis patients
To determine the expression levels of ACKR2 in PBMCs
from established PsA, RA or early RA in comparison with
healthy controls, we used qPCR as previously described
[33, 34]. As shown in Fig. 1A all three patient populations
displayed significantly elevated PBMC ACKR2 expression
relative to healthy controls. Specifically we found ACKR2
expression to be increased by a median of 2-fold in
established PsA (P = 0.005), 5-fold in established RA
(P = 0.004) and 9-fold in early RA (P = 0.0002). There
was also a significant difference in ACKR2 expression be-
tween PsA and early RA patients (P = 0.04). Some pa-
tients displayed extremely elevated levels of ACKR2
expression and, overall, there was an almost five
log spread in ACKR2 levels when data from healthy con-
trols and all three arthropathy groups were pooled
(Fig. 1B).
FIG. 1 ACKR2 expression is elevated in peripheral blood mononuclear cells from inflammatory arthropathy patients
A B
C
E
D
(A) Atypical chemokine receptor 2 (ACKR2) expression in peripheral blood mononuclear cell (PBMCs) from PsA, RA and
early RA patients compared with healthy controls. Data are expressed as fold change in expression relative to expression
in healthy control samples, the mean value for which is set as 1. (B) Compiled data showing overall spread of ACKR2
expression across healthy controls and the three patient groups. Data are expressed as fold change in expression
relative to expression in healthy control samples, the mean value for which is set as 1. (C) Cytospins of PBMCs from
healthy controls and RA patients stained for ACKR2. (D) ACKR2+ cells per view over 10 fields of view. Mean expression is
shown from seven healthy and 10 RA donors. (E) Co-staining for ACKR2 (green), and CD14, CD3 or CD20 (each in red) of
RA patient PBMCs. The overlay is shown in the third panel of the images.
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To attempt to identify the peripheral blood leucocyte
subpopulations responsible for the elevated ACKR2 ex-
pression we performed immunostaining of PBMC cytos-
pins from RA patients (Fig. 1C). Quantification of the
numbers of ACKR2-positive cells per field of view re-
vealed a highly significant increase in the percentage
ACKR2-positive cells in RA patients compared with
healthy controls (Fig. 1D). Co-staining for ACKR2 and
CD14, CD3 or CD20 indicated that ACKR2 expression
was detectable in peripheral blood monocytes, T cells
and B cells (Fig. 1E). In contrast, while a few isolated
cells with a neutrophilic morphology were seen to be posi-
tive for ACKR2 staining in healthy controls (supplementary
Fig. S2A, available at Rheumatology Online), the majority
of ACKR2-positive cells in the RA patients lacked this
morphology (supplementary Fig. S2B, available at
Rheumatology Online) suggesting little involvement of
neutrophils in contributing to the elevated ACKR2 expres-
sion. Thus elevated PBMC ACKR2 expression is seen in a
variety of leucocyte subtypes in a range of inflammatory
arthropathies.
ACKR2 expression levels do not correlate with age or
markers of disease severity
While there were significant differences between the ages
of the healthy controls and the patient groups, and also
between patient groups (supplementary Fig. S1C, avail-
able at Rheumatology Online), there was no correlation
between age and ACKR2 expression in PBMCs (supple-
mentary Fig. S3A, available at Rheumatology Online). This
suggests that age was not a contributing factor to the data
obtained. We next tested for correlations between ACKR2
expression and acute phase response markers (ESR and
CRP). This analysis showed no significant correlation be-
tween ACKR2 and ESR or CRP (supplementary Fig. S3B
and C, available at Rheumatology Online). Thus PBMC
ACKR2 expression levels do not correlate with age or dis-
ease severity in arthropathies.
ACKR2 expression correlates with peripheral blood
cytokine and chemokine levels
To attempt to define possible regulators of ACKR2 ex-
pression in PBMCs, we measured levels of a broad
range of circulating cytokines and chemokines using
Luminex and tested for correlations with PBMC ACKR2
expression levels. As shown in Fig. 2, when data from all
patient and control groups were combined, statistically
significant correlations with ACKR2 expression levels
were seen for IL-6, IL-1b, IL-2, TNF, IL-7, IL-15, IL-5 and
hepatocyte growth factor (HGF). Each correlation de-
tected was positive in the sense that increased cytokine
levels correlated with increased ACKR2 levels. By far the
most significant correlations were with IL-6 and HGF con-
centrations. In addition, for chemokines, there was a posi-
tive correlation between CCL2 levels and ACKR2
expression (Fig. 3A) and while no overall correlation was
detected with CCL3 (Fig. 3B), patients expressing ACKR2
levels above the median of the whole population display
significantly higher CCL3 levels than those below the
median (Fig. 3C). Interestingly, when broken down to dis-
ease subtypes, the strongest correlation between IL-6
levels and ACKR2 expression was seen for early RA and
between IL-1 and IL-2 and ACKR2 for PsA.
Thus ACKR2 expression in PBMCs correlates positively
with circulating levels of select cytokines and chemokines.
Combinations of cytokines and chemokines can
upregulate ACKR2 expression in PBMCs
To determine whether the correlating cytokines described
above were functionally involved in regulating ACKR2 ex-
pression we took PBMCs from healthy individuals, with
low levels of ACKR2, and tested the ability of cytokines
to increase expression levels. As shown in Fig. 2, plasma
IL-6 and HGF levels strongly correlated with PBMC
ACKR2 levels. However as shown in Fig. 4A, IL-6 was
unable to directly modulate ACKR2 expression levels in
PBMCs. In a similar manner HGF was also unable to
modulate expression levels (data not shown). Thus these
cytokines are unable to independently induce ACKR2 ex-
pression over a 48 h time frame. Next, to test combinator-
ial cytokine regulation of ACKR2 expression, we
combined the cytokines that correlated with ACKR2 to
produce a cytomix containing IL-6, IL-1b, IL-2, TNF-a,
IL-7, IL-15, IL-5 and HGF. In addition we generated a
chemomix containing the chemokines CCL2 and CCL3.
Healthy PBMCs were stimulated in vitro with these
agents following which we detected a modest but signifi-
cant and sustained increase in ACKR2 transcript levels
after stimulation with the cytomix (Fig. 4B). To determine
what contribution, if any, antigen activated T cells made to
this increase in expression, we evaluated the impact of
CD3 activation on ACKR2 expression by T cells. As
shown in supplementary Fig. S4, available at
Rheumatology Online, CD3 activation initially induced a
modest decrease in expression that became significant
by 24 h, but which was reversed at later time points
when expression in resting and activating T cells was
seen to be indistinguishable. In contrast to the cytomix,
while the data presented in Fig. 4C reveal some modest
significant differences in response to the chemomix, these
were not consistent on a temporal basis and were not
seen on repeat experiments. Overall therefore, we con-
clude that there is no increase in ACKR2 expression in
PBMCs after stimulation with the chemomix. Thus
PBMC expression of ACKR2 correlates with select circu-
lating cytokines, and mixtures of these cytokines are cap-
able of increasing ACKR2 expression, suggesting a
functional association in peripheral blood.
Expression of ACKR2 within RA synovium
Next we used immunohistochemistry to examine expres-
sion of ACKR2 in RA synovium. Initial staining (Fig. 5A)
revealed ACKR2-positive signals associated with cells at
the tissuesynovial fluid interface as well as on numerous
cells internal to the synovial tissue structure. Co-staining
for CD45 and ACKR2 (Fig. 5B) demonstrated that the
receptor is expressed by numerous leucocytes but also
by stromal cells throughout the tissue. Interestingly,
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Expression of ACKR2 in inflammatory arthritis
Downloaded from https://academic.oup.com/rheumatology/article-abstract/56/9/1607/3807061/Elevated-ACKR2-expression-is-a-common-feature-of
by University of Glasgow user
on 17 October 2017
ACKR2-positive leucocytes were generally not randomly
distributed within the tissue and were present predomin-
antly within leucocyte aggregates. Notably, co-staining for
ACKR2 and one of its ligands, CCL3, indicates that there
is significant overlap in their expression patterns and that
ACKR2 is therefore expressed at appropriate tissue pos-
itions for effective intra-synovial chemokine scavenging
(Fig. 5C). We have previously reported expression of
ACKR2 by T cells, B cells, monocytic cells and mast
cells [33]. In agreement with this, co-staining for CD45
and markers specific to these leucocyte populations
demonstrated ACKR2 expression on these cellular
populations (Fig. 6AD). Particularly strong co-staining
was seen with aggregates of T and B cells (Fig. 6B and
C) suggestive of ACKR2 expression within ectopic fol-
licles. Thus ACKR2 is expressed in both leucocyte, and
non-leucocyte, populations within the synovium, coinci-
dent with expression of inflammatory CC-chemokines.
Discussion
ACKR2 is an important regulator of inflammation and we
have previously reported marked upregulation of expres-
sion in skin and peripheral blood leucocytes in psoriasis
FIG. 2 Correlation of ACKR2 expression in peripheral blood mononuclear cells with plasma cytokines
Peripheral blood mononuclear cells (PBMCs) and paired serum samples were taken from healthy controls, PsA patients, RA
patients or early RA patients. Atypical chemokine receptor 2 (ACKR2) expression was measured using qPCR with absolute
quantification and normalized to 106 copies of TATA-binding protein (TBP). Plasma was analysed by 30-plex luminex
analysis. ACKR2 expression is shown against significantly correlating cytokines: IL-6, IL-1b, IL-2, TNF-a, IL-7, IL-15, IL-5
and hepatocyte growth factor (HGF). Correlation analysis was performed using Spearman’s correlation coefficient.
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[22] and SSc [23], and others have shown increased ex-
pression in chronic obstructive pulmonary disease [24]
and post-myocardial infarction tissues [25]. The purpose
of the present study was to extend these observations
and to examine expression of ACKR2 in arthropathies.
Here we present data demonstrating upregulation of
ACKR2 in PsA, RA and early RA. We conclude, on this
basis, that elevated peripheral blood ACKR2 expression is
a consistent feature of inflammatory pathologies. We fur-
ther demonstrate an association between select circulat-
ing cytokines and ACKR2 expression and show that
mixtures of these cytokines are capable of increasing
ACKR2 expression levels in healthy PBMCs. Notably,
the increase in ACKR2 expression in response to cytokine
treatment was modest. The fact that the cytokines were
used at a high concentration, relative to their likely in vivo
concentrations, and that cytokines do not demonstrate
bell-shaped doseresponse curves, suggests that it is
FIG. 4 Regulation of ACKR2 expression by cytokines and
chemokines
A
B
C
(A) Healthy peripheral blood mononuclear cells (PBMCs)
were treated with PBS or IL-6 in the presence or ab-
sence of soluble IL-6 receptor (IL-6R) for 6, 24 and 48 h.
Atypical chemokine receptor 2 (ACKR2) expression as-
sessed using qPCR. Data are expressed as ACKR2
copies/106 copies of TATA binding protein. PBMCs were
obtained from one donor. These data are representative
of two replicate experiments. (B) Cytokines were pooled
into a cytomix containing IL-6, IL-1b, IL-2, TNF-a, IL-7,
IL-15, IL-5 and HGF (all at 100 ng/ml) and the mix used
to stimulate PBMCs for 6, 24 and 48 h. Expression of
ACKR2 was assessed as above. PBMCs were obtained
from one donor. These data are representative of two
replicate experiments. (C) A chemomix containing CC
chemokine ligand (CCL) 2 and CCL3 (both at 10 mg/ml)
was used to stimulate PBMCs, and ACKR2 expression
measured. PBMCs were obtained from one donor.
These data are representative of two replicate
experiments.
FIG. 3 Correlation of ACKR2 expression in peripheral
blood mononuclear cells with ACKR2-binding chemokines
A
B
C
Peripheral blood mononuclear cells (PBMCs) and paired
plasma samples were taken from healthy controls, PsA
patients, RA patients or early RA patients. Atypical che-
mokine receptor 2 (ACKR2) expression was measured
using qPCR with absolute quantification and normalized
to 106 copies of TATA-binding protein (TBP). Plasma was
analysed by 30-plex Luminex analysis. (A, B) ACKR2 ex-
pression is shown correlated with CC chemokine ligand
(CCL) 2 (A) and CCL3 (B). (C) CCL3 levels between
ACKR2-high and ACKR2-low patients. Correlation ana-
lysis was performed using Spearman’s correlation
coefficient.
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likely that this modest increase is the maximum that can
be achieved with this cytokine mix. The relevance of this
increase remains to be determined, especially given that
the differences detected are at the transcriptional level
and not the protein level. One further consideration is
whether sufficient time was given in these experiments
for effective induction of ACKR2 expression by the cyto-
kine mix. Our previous studies have shown robust induc-
tion of ACKR2 by a variety of cytokines in a variety of cell
types within a period of 2448 h [22, 33, 34, 36]. We there-
fore do not anticipate that prolonged incubation with the
cytokine mix beyond 48 h will lead to increased ACKR2
expression. The strongest association between circulating
cytokines and ACKR2 expression was seen for IL-6 and
HGF although neither cytokine alone was capable of indu-
cing ACKR2 expression. Interestingly, while a similar as-
sociation with HGF was seen in psoriatic patients, these
patients displayed no association between IL-6 and
ACKR2 (data not shown). This contrasts with the
ACKR2-inducing effects of IL-6 seen on lymphatic endo-
thelial cells [34]. Together our observations suggest alter-
native molecular drivers for enhanced ACKR2 expression
in different inflammatory pathologies and cell types.
Surprisingly in the arthropathy groups studied (as well
as in psoriatic patients) there is no apparent correlation
between peripheral blood ACKR2 expression and dis-
ease severity (supplementary Fig. S3, available at
Rheumatology Online). As circulating inflammatory CC-
chemokines will predominantly have derived from the ori-
ginal inflamed site, one intriguing possibility is that ACKR2
limits the activity of circulating chemokines and therefore
potentially ameliorates the development of chemokine-
associated comorbidities (e.g. atherosclerosis) in patients.
This possibility, however, remains to be tested.
In addition we demonstrate expression of ACKR2 in
both leukocytes and resident stromal populations in pa-
tient synovial biopsies. The demonstration of expression
on stromal cells, especially those at the synoviumSF
FIG. 5 ACKR2 is expressed within the RA synovium in leucocytes and stromal cells
A
B
C
(A) Paraffin embedded RA synovial tissue sections (5 mm) were stained for atypical chemokine receptor 2 (ACKR2). Slides
were counterstained with haematoxylin. (B) Co-staining for ACKR2 (green) and CD45 (red) and showing the overlay of the
two stains (yellow) on paraffin-embedded synovial tissue sections. Slides were counterstained with 40,6-diamidino-2-
phenylindole (DAPI; blue). (C) Paraffin embedded RA synovial tissue sections were stained for ACKR2 (green) and CC
chemokine ligand 3 (CCL3; red). The third image shows the overlay of the two colours. Slides were counterstained with
DAPI.
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FIG. 6 ACKR2 is expressed within RA synovium on defined leucocyte subpopulations
A
B
C
D
E
F
(AE) Paraffin embedded rheumatoid arthritis synovial tissue sections (5 mm) were stained for atypical chemokine re-
ceptor 2 (ACKR2) (green) together with CD45 (A), CD3 (B), CD20 (C), CD68 (D) or mast cell tryptase (MCT) (E) to identify
leucocytes within the synovium expressing ACKR2. Yellow represents the overlay of the two colours and indicates
coincident expression. Slides were counterstained with 40,6-diamidino-2-phenylindole (DAPI) and visualized on a Zeiss
epifluorescence microscope with AxioVision v. 4.8.2 software. (F) Percentages of ACKR2+ lineage+ cells quantified over
10 fields of view.
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interface, extends observations made in psoriatic skin that
demonstrated inducible expression on keratinocytes [22].
We hypothesize that stromal cell expression serves to
reduce inflammatory chemokine bio-availability, or to
limit its domain of influence, and this is supported by the
coincident expression of ACKR2 and CCL3 in synovial
tissues. Strikingly, many of the leukocytes that are positive
for ACKR2 expression are B and T cells present in large
leucocyte aggregates within the synovial tissues. We pro-
pose that these correspond to ectopic follicles although
the role of ACKR2 within these structures is not immedi-
ately apparent. It may be that ACKR2 is important to
ensure the relative absence of inflammatory leucocytes
within these ectopic lymphoid follicles [37, 38].
In summary, therefore, we provide evidence demon-
strating upregulation of ACKR2 in peripheral blood cells
and in cells within the synovium. This, coupled with pre-
vious observations from psoriasis and SSc patients sug-
gests that elevated ACKR2 levels are a consistent feature
of many human inflammatory pathologies. Further work is
required to determine the functional implications of ele-
vated expression in these pathological contexts.
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